# Paper
## Introduction
### Trismus Definition and Impact
- [[@dijkstraCriteriaTrismusHead2006]]: Definition
- [[@weberLimitedMouthOpening2010]]: QOL impact
- [[@scottFactorsAssociatedRestricted2008]]: QOL impact
- [[@louisekentRadiationInducedTrismusHead2008]]: QOL impact
	- [ ] update trismus impact with more modern data (post-2010)

### Existing Therapies and Effectiveness
- [[@carvalhoInterventionsPreventingTreating2016]]: Cochrane. Good outline of interventions.
	- [ ] extract citations from this

#### Dynasplint
- [[@barananoDynasplintManagementTrismus2011]]: Nice mm/day #
- [[@shulmanTreatingTrismusDynamic2008]]: 13.6 mm change after RT
- [[@stubblefieldPreliminaryReportEfficacy2010]]: 7 mm change over 118 days

#### TheraBite
- [[@scherpenhuizenEffectExerciseTherapy2015]]: nice systematic review. Pull numbers from here (convert to mm/week \[95% CI] and plot)
- [[@pauliExerciseInterventionTreatment2014]]: 6.4 mm/10wk
- [[@buchbinderMobilizationRegimensPrevention1993]]: 13.6 mm/10wk

#### Systemic Therapy
- [[@chuaPilotStudyPentoxifylline2001]]: Pentoxifylline 4 mm/8 weeks
- [[@danaBotulinumToxinRadiationinduced2008]]: Botulinum â†’ no effect

### Boswellia
#### Description
- [[@lulliAcetyl11ketovboswellicAcidReduces2015]]: MOA: VEGF/STAT3 reduced expression
- [[@poeckelBoswellicAcidsBiological2006]]: MOA: 5-Lipoxygenase, human leukocyte elastase, topoisomerase I/II, NFKB
- [[@safayhiInhibitionBoswellicAcids1997]]: MOA: Human leukocyte elastase inhibition

#### Literature
##### CNS
- [[@upadhyayRoleBoswelliaSerrata2023]]: Case report: 90% improvement in FLAIR enhancement/edema at 5 months
- [[@warnickTreatmentAdverseRadiation2023]]: Case series: 5-Loxin as salvage treatment for refractory AREs and persistent edema. Resolution of symptoms/imaging changes, discontinuation of steroids, no medications side effects
- [[@dipierroNovelLecithinbasedDelivery2019]]
- [[@kirsteBoswelliaSerrataActs2011]]: GBM RCT
##### Asthma
- [[@guptaEffectsBoswelliaSerrata1998]]: double-blind RCT: 70% with improvement in asthma symptoms (compated to 27% in control group)

##### Crohns
- [[@gerhardtTherapyActiveCrohn2001]]: double-blind RCT: BS non-inferior to mesalazine

##### Collagenous colitis
- [[@madischBoswelliaSerrataExtract2007]]: blinded RCT: 64 vs 27% clinical remission with BS

##### OA
- [[@kimmatkarEfficacyTolerabilityBoswellia2003]]: double-blind RCT: significant reductions in pain, loss of movement, swelling
- [[@thawaniOpenRandomizedControlled2007]]: open RCT: BS with significant improvement in ADL ability

## Case Presentation
### Patient Background
### Initial Presentation
### Workup
### Treatment
### Trismus: Development and Treatment

## Discussion
- [ ] consider comparing patient's rates of change with those from Pauli 2014 and Buchbinder 1993 Therabite data (including 95% CI).

## Lesons/Conclusions